NOVOZYMES A/S SPONS.ADR 1 Cash Flow Quality Index
NOVOZYMES A/S SPONS.ADR 1 cash flow quality index. NOVOZYMES A/S SPONS.ADR 1 (NZM) has a Cash Flow Quality Index of 0.84x as of March 2026. Operating cash flow of €167.10 Million is below net income of €199.10 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore NOVOZYMES A/S SPONS.ADR 1 (NZM) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of NOVOZYMES A/S SPONS.ADR 1 (2021–2025)
Cash flow quality index of NOVOZYMES A/S SPONS.ADR 1 from 2021 to 2025. Historical Cash Flow Quality Index for NOVOZYMES A/S SPONS.ADR 1 across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. See NOVOZYMES A/S SPONS.ADR 1 balance sheet quality to measure how much of total assets are equity-financed.
NOVOZYMES A/S SPONS.ADR 1 Cash Flow Quality Index by Year (2021–2025)
NOVOZYMES A/S SPONS.ADR 1 cash flow quality index by year from 2021 to 2025. Year-by-year earnings quality comparison for NOVOZYMES A/S SPONS.ADR 1. For the full cash flow conversion analysis, see cash efficiency ratio of NOVOZYMES A/S SPONS.ADR 1.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 2.09x | €1.22 Billion | €583.60 Million | ▲ +368.1% |
| 2024 | 0.45x | €1.02 Billion | €2.28 Billion | ▲ +142.7% |
| 2023 | 0.18x | €557.10 Million | €3.02 Billion | ▲ +26.0% |
| 2022 | 0.15x | €537.65 Million | €3.68 Billion | ▼ -88.7% |
| 2021 | 1.29x | €546.17 Million | €423.00 Million | — |